Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001

MeSH terms

• Adrenergic beta-Antagonists / adverse effects
• Adrenergic beta-Antagonists / therapeutic use
• Advisory Committees*
• Age Factors
• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors / therapeutic use
• Black People / genetics
• Black or African American
• Canada
• Cardiovascular Agents / adverse effects*
• Cardiovascular Agents / therapeutic use
• Drug Approval*
• Heart Failure / drug therapy*
• Heart Failure / genetics
• Heart Failure / mortality
• Humans
• Hyperkalemia / etiology
• Randomized Controlled Trials as Topic / methods
• Randomized Controlled Trials as Topic / statistics & numerical data*
• Receptor, Angiotensin, Type 1
• Renal Insufficiency / etiology
• Spironolactone / adverse effects
• Spironolactone / therapeutic use
• Survival Rate
• Tetrazoles / adverse effects*
• Tetrazoles / therapeutic use
• United States
• United States Food and Drug Administration
• Valine / adverse effects*
• Valine / analogs & derivatives*
• Valine / therapeutic use
• Valsartan